2025-04-29 21:20:28
Latest Post
Bajaj Finance Ltd reports jump in Q4 FY25 consolidated PAT to Rs. 4479.57 crores
CIL Securities Ltd Q4 FY25 profit down at Rs. 42.60 lakhs
Five-Star Business Finance Ltd Q4 FY2024-25 net profit increases to Rs. 279.12 crores
Delphi World Money Ltd Q4 FY2025 profit up QoQ at Rs. 2.87 crore
Nath Bio-Genes India Ltd Q4 FY25 consolidated net profit slips to Rs. 1.48 crore
Stock Report
Godavari Drugs Ltd Q4 FY2023 PAT up QOQ at Rs. 1.33 crore
Posted On : 2023-05-29 18:27:36( TIMEZONE : IST )
GODAVARI DRUGS LTD. has reported Standalone financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 37.5277 crores during the period ended March 31, 2023 as compared to Rs. 39.4567 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 1.3313 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. 0.6691 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 1.77 for the period ended March 31, 2023 as compared to Rs. 0.89 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹37.5277 crs | ₹39.4567 crs |  -4.89% |
| Net Profit | ₹1.3313 crs | ₹0.6691 crs |  98.97% |
| EPS | ₹1.77 | ₹0.89 | 98.88% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.37.5277 crores during the period ended March 31, 2023 as compared to Rs.44.3961 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.1.3313 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.1.2675 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.1.77 for the period ended March 31, 2023 as compared to Rs.1.68 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹37.5277 crs | ₹44.3961 crs | -15.47% |
| Net Profit | ₹1.3313 crs | ₹1.2675 crs | 5.03% |
| EPS | ₹1.77 | ₹1.68 | 5.36% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.160.2801 crores during the Financial Year ended March 31, 2023 as compared to Rs.161.3825 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.3.7858 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.5.2453 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.5.03 for the Financial Year ended March 31, 2023 as compared to Rs.6.97 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹160.2801 crs | ₹161.3825 crs | -0.68% |
| Net Profit | ₹3.7858 crs | ₹5.2453 crs | -27.82% |
| EPS | ₹5.03 | ₹6.97 | -27.83% |
Shares of GODAVARI DRUGS LTD. was last trading in BSE at Rs. 86.03 as compared to the previous close of Rs. 87.47. The total number of shares traded during the day was 17645 in over 148 trades.
The stock hit an intraday high of Rs. 89.89 and intraday low of 83.95. The net turnover during the day was Rs. 1500606.00.
